Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2008 3
2009 1
2010 2
2011 2
2012 2
2013 8
2014 9
2015 7
2016 4
2017 3
2018 7
2019 11
2020 14
2021 10
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

70 results
Results by year
Filters applied: . Clear all
Page 1
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H. Kalincik T, et al. Among authors: van wijmeersch b. J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):458-468. doi: 10.1136/jnnp-2018-319831. Epub 2019 Jan 13. J Neurol Neurosurg Psychiatry. 2019. PMID: 30636699
Effects of an individual 12-week community-located "start-to-run" program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis.
Feys P, Moumdjian L, Van Halewyck F, Wens I, Eijnde BO, Van Wijmeersch B, Popescu V, Van Asch P. Feys P, et al. Among authors: van wijmeersch b. Mult Scler. 2019 Jan;25(1):92-103. doi: 10.1177/1352458517740211. Epub 2017 Nov 8. Mult Scler. 2019. PMID: 29113572 Clinical Trial.
Determinants of therapeutic lag in multiple sclerosis.
Roos I, Leray E, Frascoli F, Casey R, Brown JWL, Horakova D, Havrdova EK, Debouverie M, Trojano M, Patti F, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Grammond P, Ciron J, Ruet A, Ozakbas S, De Seze J, Louapre C, Zephir H, Sá MJ, Sola P, Ferraro D, Labauge P, Defer G, Bergamaschi R, Lebrun-Frenay C, Boz C, Cartechini E, Moreau T, Laplaud D, Lechner-Scott J, Grand'Maison F, Gerlach O, Terzi M, Granella F, Alroughani R, Iuliano G, Van Pesch V, Van Wijmeersch B, Spitaleri D, Soysal A, Berger E, Prevost J, Aguera-Morales E, McCombe P, Castillo Triviño T, Clavelou P, Pelletier J, Turkoglu R, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Sidhom Y, Gouider R, Csepany T, Bourre B, Al Khedr A, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanche JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Coles A, Malpas CB, Vukusic S, Butzkueven H, Kalincik T. Roos I, et al. Among authors: van wijmeersch b. Mult Scler. 2021 Oct;27(12):1838-1851. doi: 10.1177/1352458520981300. Epub 2021 Jan 11. Mult Scler. 2021. PMID: 33423618 Free article.
Deciphering the Morphology of Motor Evoked Potentials.
Yperman J, Becker T, Valkenborg D, Hellings N, Cambron M, Dive D, Laureys G, Popescu V, Van Wijmeersch B, Peeters LM. Yperman J, et al. Among authors: van wijmeersch b. Front Neuroinform. 2020 Jul 14;14:28. doi: 10.3389/fninf.2020.00028. eCollection 2020. Front Neuroinform. 2020. PMID: 32765249 Free PMC article.
Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score.
Kunchok A, Lechner-Scott J, Granella F, Trojano M, Alroughani R, Sola P, Ferraro D, Lugaresi A, Onofrj M, Ozakbas S, Izquierdo G, Grammond P, Luis Sanchez-Menoyo J, Van Wijmeersch B, Boz C, Pucci E, McCombe P, Grand'Maison F, Spitaleri D, Vucic S, Hupperts R, Jokubaitis V, Sormani MP, Butzkueven H, Kalincik T; MSBase Study Group. Kunchok A, et al. Among authors: van wijmeersch b. Mult Scler. 2021 Apr;27(5):695-705. doi: 10.1177/1352458520936823. Epub 2020 Jul 8. Mult Scler. 2021. PMID: 32639855
The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective.
Alroughani R, Van Wijmeersch B, Al Khaboori J, Alsharoqi IA, Ahmed SF, Hassan A, Inshasi J, Krieger DW, Shakra M, Shatila AO, Szolics M, Khallaf M, Ezzat A. Alroughani R, et al. Among authors: van wijmeersch b. Ther Adv Neurol Disord. 2020 Sep 16;13:1756286420954119. doi: 10.1177/1756286420954119. eCollection 2020. Ther Adv Neurol Disord. 2020. PMID: 32973927 Free PMC article. Review.
Optimizing therapy early in multiple sclerosis: An evidence-based view.
Ziemssen T, De Stefano N, Sormani MP, Van Wijmeersch B, Wiendl H, Kieseier BC. Ziemssen T, et al. Among authors: van wijmeersch b. Mult Scler Relat Disord. 2015 Sep;4(5):460-469. doi: 10.1016/j.msard.2015.07.007. Epub 2015 Jul 17. Mult Scler Relat Disord. 2015. PMID: 26346796 Free article. Review.
Risk of secondary progressive multiple sclerosis: A longitudinal study.
Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, Girard M, Duquette P, Lugaresi A, Izquierdo G, Grand'Maison F, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Hupperts R, Boz C, Lechner-Scott J, Pucci E, Bergamaschi R, Van Pesch V, Ozakbas S, Granella F, Turkoglu R, Iuliano G, Spitaleri D, McCombe P, Solaro C, Slee M, Ampapa R, Soysal A, Petersen T, Sanchez-Menoyo JL, Verheul F, Prevost J, Sidhom Y, Van Wijmeersch B, Vucic S, Cristiano E, Saladino ML, Deri N, Barnett M, Olascoaga J, Moore F, Skibina O, Gray O, Fragoso Y, Yamout B, Shaw C, Singhal B, Shuey N, Hodgkinson S, Altintas A, Al-Harbi T, Csepany T, Taylor B, Hughes J, Jun JK, van der Walt A, Spelman T, Butzkueven H, Kalincik T. Fambiatos A, et al. Among authors: van wijmeersch b. Mult Scler. 2020 Jan;26(1):79-90. doi: 10.1177/1352458519868990. Epub 2019 Aug 9. Mult Scler. 2020. PMID: 31397221
Cytomegalovirus infection exacerbates autoimmune mediated neuroinflammation.
Vanheusden M, Broux B, Welten SPM, Peeters LM, Panagioti E, Van Wijmeersch B, Somers V, Stinissen P, Arens R, Hellings N. Vanheusden M, et al. Among authors: van wijmeersch b. Sci Rep. 2017 Apr 6;7(1):663. doi: 10.1038/s41598-017-00645-3. Sci Rep. 2017. PMID: 28386103 Free PMC article.
70 results